Anoro Ellipta (Umeclidinium/Vilanterol) Shortage: What Providers and Prescribers Need to Know in 2026

Across pulmonology practices, primary care clinics, and geriatric offices, one question is becoming increasingly common: "My patient can't find Anoro Ellipta. What do I do?"

This guide provides clinicians with a concise, up-to-date overview of Anoro Ellipta (umeclidinium/vilanterol) availability in 2026, the clinical implications for your COPD patients, and a practical framework for managing through these access challenges.

Current FDA Status: Not in Official Shortage

As of 2026, Anoro Ellipta (umeclidinium/vilanterol 62.5/25 mcg) does not appear on the FDA's official drug shortage database. At the national supply level, adequate quantities of both the brand and authorized generic (Prasco Laboratories) are being produced.

However, individual pharmacy availability is inconsistent, and patients are experiencing real-world access barriers. Clinicians should be prepared to discuss alternatives and assist with insurance navigation.

Why Patients Are Having Trouble Filling Prescriptions

Several factors are driving prescription access challenges in 2025-2026:

• Authorized generic transition: Prasco Laboratories launched an FDA-approved generic in 2025. Brand-to-generic transitions routinely cause 6-12 months of supply chain disruption as pharmacies, wholesalers, and PBMs adjust purchasing decisions.
• Formulary repositioning: Some PBMs and Medicare Part D plans have added prior authorization or step-therapy requirements as the generic becomes available, causing delays in patient access.
• Stocking variability: Chain pharmacies with lower COPD patient volumes may not stock Anoro Ellipta or the generic consistently. Independent and specialty respiratory pharmacies tend to maintain more reliable inventory.

Clinical Implications of Missed Doses

Umeclidinium/vilanterol is a maintenance bronchodilator. Missed doses in patients with moderate-to-severe COPD (GOLD Stage II-III) can result in:

• Increased dyspnea and reduced exercise tolerance
• Increased rescue inhaler use (a sign of deteriorating control)
• Acute COPD exacerbations requiring emergency department visits or hospitalization
• Deterioration in FEV1 and overall pulmonary function

Bridging to an equivalent medication promptly is preferable to leaving a patient without maintenance bronchodilation.

Therapeutic Alternatives: A Clinical Framework

When Anoro Ellipta is unavailable or unaffordable, consider the following evidence-based alternatives:

• First: Check for the authorized generic. Generic umeclidinium/vilanterol (Prasco) is bioequivalent and uses the same Ellipta device. Prescribing "umeclidinium/vilanterol 62.5/25 mcg inhalation powder" as the generic should be accessible to most patients. This is the most seamless transition.
• Stiolto Respimat (tiotropium/olodaterol): The closest pharmacological alternative — also a LAMA/LABA dual bronchodilator, dosed once daily. Uses a soft mist inhaler, which some patients with reduced inspiratory flow find easier to use than the Ellipta DPI.
• Bevespi Aerosphere (glycopyrrolate/formoterol): LAMA/LABA MDI, dosed twice daily. Note the frequency change if switching from Anoro's once-daily regimen.
• Trelegy Ellipta (fluticasone/umeclidinium/vilanterol): Appropriate step-up for patients with frequent exacerbations (≥2/year), higher blood eosinophils (≥300 cells/μL), or concomitant asthma features. Contains the same active components as Anoro Ellipta plus ICS.
• Tiotropium (Spiriva) monotherapy: Acceptable short-term bridge for lower-risk patients who cannot access dual bronchodilation. Generic tiotropium offers significant cost savings.

39,453+ patients found their medications in stock

39K+

Find Umeclidinium/Vilanterol In Stock Today →

Insurance Navigation for Clinicians

When patients face access barriers due to insurance, consider these strategies:

• Prior authorization: When submitting PA requests, emphasize GOLD staging, FEV1/FVC ratio, exacerbation history, and failure or contraindication to step-therapy alternatives. Include the clinical rationale for maintaining dual bronchodilation.
• Appeal denials: GOLD 2024 guidelines support dual LAMA/LABA therapy for symptomatic COPD patients (mMRC ≥2 or CAT score ≥10) who remain uncontrolled on monotherapy. Use these references in PA appeals.
• GSK patient assistance: Uninsured and income-eligible patients can receive Anoro Ellipta at no cost through the GSK For You Patient Assistance Program. Call 888-825-5249 or visit gskpaf.org. Your office can assist patients in completing applications.

A Resource for Your Patients

Consider directing patients to medfinder for providers — a service that calls pharmacies on patients' behalf to locate in-stock medications. For COPD patients with mobility limitations or difficulty using the phone, this removes a significant barrier to getting their maintenance inhaler filled.

Skip the calls, skip the stress.

Find Umeclidinium/Vilanterol In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Takeaways for Clinicians

• Anoro Ellipta is not in an official FDA shortage in 2026, but patients are experiencing real access barriers due to brand-to-generic transition and variable pharmacy stocking
• Always check for the authorized Prasco generic first — same device, same drug, potentially better availability
• Stiolto Respimat is the closest pharmacological alternative for patients who cannot access Anoro or its generic
• Do not leave moderate-to-severe COPD patients without maintenance bronchodilation — bridge quickly with an appropriate alternative
• GSK For You PAP provides free medication for uninsured, income-eligible patients